REG - Abingdon Health PLC - Notice of Annual General Meeting

Abingdon HealthAnnouncement

22/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231122:nRSV0114Ua&default-theme=true

RNS Number : 0114U  Abingdon Health PLC  22 November 2023

                Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Notice of Annual General Meeting

 

York, U.K. 22 November 2023: Abingdon Health plc (AIM: ABDX), a leading
international developer and manufacturer of high quality, rapid diagnostic
tests, announces that its Annual General Meeting ('AGM') will be held on
Friday 15 December 2023 at 9.30 a.m. at the offices of Abingdon Health, York
Biotech Campus, Sand Hutton, York, YO41 1LZ, United Kingdom.

 

The notice convening the AGM will be sent to shareholders today and is
available on the Company's website www.abingdonhealth.com
(http://www.abingdonhealth.com) .

 

Enquiries:

 

 Abingdon Health plc                                                   www.abingdonhealth.com/investors/
                                                             (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                        Via Walbrook PR
 Chris Hand, Non-Executive Chairman

 Singer Capital Markets (Sole Broker and Nominated Adviser)  Tel: +44 (0)20 7496 3000
 Peter Steel, Alex Bond, Jalini Kalaravy

 Walbrook PR Limited                                         Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                                             (mailto:abingdon@walbrookpr.com)
 Paul McManus                                                +44 (0)7980 541 893
 Phillip Marriage                                                          +44 (0)7867 984 082
 Alice Woodings                                                            +44 (0)7407 804 654

 

About Abingdon Health plc

Abingdon Health is a leading lateral flow contract development and
manufacturing organisation ("CDMO") offering its services to an international
customer base across industry sectors that include clinical, animal health,
plant health, and environmental testing. Abingdon Health has the internal
capabilities to take projects from initial concept through to routine and
large-scale manufacturing; from "idea to commercial success."

 

The Company's CDMO division offers product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format. Abingdon Health aims to support the increase in need for rapid
results across many industries and locations and produces lateral flow tests
in areas such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making, targeted intervention and can support better
outcomes.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com) ecommerce site offers consumers a range of
information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range is also sold through international distributors and through other
channels in the UK and Ireland such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAURSAROVUAUAA